Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

S and AML Patients

CHICAGO, Ill. June 2, 2007 - Pharmion Corporation (NASDAQ:PHRM) and MethylGene Inc. (TSX:MYG) today announced preliminary Phase II and Phase I/II data for their lead oncology product candidate, MGCD0103, a novel, isotype-selective histone deacetylase (HDAC) inhibitor which showed significant anti-tumor activity in patients with Hodgkin's lymphoma, Myelodysplastic Syndromes and acute myelogenous leukemia. The data were presented Saturday at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Hodgkin's Lymphoma (Trial 010)

Data presented show an objective complete and partial response rate of 40 percent and a disease control rate of 45 percent in a population of patients that had relapsed disease or were refractory (unresponsive) to all previous treatments, including, in many cases, bone marrow transplantation. Overall, 75 percent of patients experienced a reduction in tumor size, with 60 percent experiencing a tumor reduction of greater than 30 percent.

"It is striking that single-agent therapy with MGCD0103 achieved such impressive objective clinical responses in this population," said Anas Younes, M.D., principal investigator and Professor of Medicine and Director, Clinical Investigation and Translational Research in the Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center. "No approved therapies exist for patients suffering from Hodgkin's lymphoma that has progressed following transplantation. With a novel mechanism of action and an oral route of administration, MGCD0103 would be a welcome and desirable addition to the Hodgkin's lymphoma armamentarium."

The data were presented as part of a clinical symposium titled, "Breaking the Silence of the Genome: HDAC Inhibitors," which focused on the progress and potential of this emerging therapeutic category. The HDACs are enzymes that mediate histone deacetylation, an epigenetic form of gene regulation that may silence tumor suppres
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... YORK, Sept. 9 New York Blood Center (NYBC), serving ... Island, the Hudson Valley and New Jersey, calls upon our ... and Labor Day holiday weekend have resulted in fewer donations ... B-negative blood for patients in need. Donations from ...
... Polycystic Ovarian Syndrome, known as PCOS, is a silent ... body and increases the risk of serious illness. ... and increases the risk of heart disease, insulin resistance, diabetes ... abnormality in women of child bearing age, affecting 5 to ...
Cached Medicine Technology:Blood Donors Needed as School, Fall Season Returns 2Blood Donors Needed as School, Fall Season Returns 3Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 3
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician ... practices; OB GYN in Melrose Park, IL and ... contains important information about each of the care services and ... forms in English and Spanish. The navigation of the ... the website provide Dr. Furlin’s patients with important information regarding ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... have newly identified 34 unique variations in the human ... sclerosis (ALS). ,The 34 so-called single nucleotide ... to the non-inherited form of the fatal neurodegenerative disease. ... responsible for sporadic ALS, our results seriously narrow the ...
... arteries and giving blood at six-monthly intervals to promote iron reduction ... ,A normal adult has five to six litres of blood ... blood donation. This blood is replaced by the body within 24 ... VA Medical Centre and the Dartmouth Medical School in Vermont looked ...
... for primary ciliary dyskinesia, a rare genetic disease that ... ,According to Thomas Ferkol, M.D., Washington University School of ... of patients with primary ciliary dyskinesia (PCD) have a ... of PCD requires a high index of suspicion, but ...
... such as Tenormin, Inderal and Lopressor should not be a ... a large new review of studies. ,The review, ... that beta-blocker users have a slightly higher risk of death ... such as Norvasc and Cardizem to manage their blood pressure. ...
... determined that low levels of a protein in the blood ... artery disease. ,In a group of men ... Activation, Normal T-cell Expressed, and Secreted), also known as CCL5, ... ,RANTES is a chemokine produced by a variety ...
... breast cancer prevention among women at high risk of the ... found that the breast cancer risk reduction persists long after ... to treat breast cancer and to prevent it among women ... data on tamoxifen for breast cancer prevention comes from the ...
Cached Medicine News:Health News:Human Genetic Code for ALS Identified 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3Health News:Beta-Blockers Should Not Be First Choice for High Blood Pressure 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: